Superworth

Fennec Pharmaceuticals revenue FENC

Sales by quarter and over the last twelve months, from 2011.

Last 12 months, to Jun 30, 2026
$59.2M
Latest quarter, Q2 FY26
$17.9M
+85% on a year earlier
Fiscal year 2025
$44.6M
−6% on the year before

Fennec Pharmaceuticals' revenue was $59.2M over the twelve months to Jun 30, 2026, up 78% on a year earlier.

In its latest quarter, Q2 FY26, it was $17.9M, up 85% on the same quarter a year before.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$44.6M−6%
FY2024$47.5M+124%
FY2023$21.3M+12401%
FY2020$170Kn/a
FY2019$0n/a
FY2018$0n/a
FY2017$0n/a
FY2016$0n/a
FY2015$0n/a
FY2014$0n/a
FY2013$0n/a
FY2012$0n/a
FY2011$0n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$17.9M+85%$59.2M
Q1 FY26$15.1M+73%$51M
Q4 FY25$13.8M+74%$44.6M
Q3 FY25$12.5M+79%$38.8M
Q2 FY25$9.7M+33%$33.3M
Q1 FY25$8.8M−66%$30.9M
Q4 FY24$7.9M−19%$47.5M
Q3 FY24$7M+7%$49.3M
Q2 FY24$7.3M+118%$48.9M
Q1 FY24$25.4M+1413%$45M
Q4 FY23$9.7Mn/a$21.3M
Q3 FY23$6.5Mn/an/a

Against its peers

Companies in Biotechnology nearest Fennec Pharmaceuticals' size, closest first, today.

CompanyRevenue, 12 monthsGrowth
FENCFennec Pharmaceuticals$59.2M+78% a year
PLXProtalix BioTherapeutics$80.6M+30% a year
MGTXMeiraGTx$397.5M
VCELVericel$306.3M+23% a year
ADMAAdma Biologics$512.3M+8% a year
Peer median$351.9M

Where Fennec Pharmaceuticals ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Fennec Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.